Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2024.04.30
ag真人平台官方：关于2023年年度股东大会增加临时提案暨股东大会补充通知的公告
2024.04.30
ag真人平台官方：董事会决议公告
2024.04.30
ag真人平台官方：关于举行2023年年度业绩说明会的公告
2024.04.02
ag真人平台官方：关于依诺肝素钠制剂获得泰国药品注册批件的公告
2024.03.29
ag真人平台官方：未来三年（2024年-2026年）股东回报规划
2024.03.29
ag真人平台官方：商誉减值测试报告
2024.03.29
ag真人平台官方：关于依诺肝素钠制剂获得新西兰药品注册批件的公告
2024.03.29
ag真人平台官方：关于使用自有资金购买理财产品及进行现金管理的公告
2024.03.29
ag真人平台官方：关于开展以套期保值为目的的外汇衍生品交易的公告
2024.03.29
ag真人平台官方：关于公司2023年计提资产减值准备的公告
第一页
上一页
1
2
3
4
5
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
